Adia Nutrition Inc. Files for OTCQB Uplisting with OTC Markets, Emphasizing OTC-Handled 15c2-11 for Transparency and Investor Reach
Rhea-AI Summary
Adia Nutrition Inc. (OTC Pink: ADIA) has filed for uplisting to the OTCQB Venture Market following a successful independent audit with Astra Audit and Advisory on April 1, 2025. The company specializes in regenerative medicine and nutritional wellness, focusing on stem cell therapies and nutritional products.
As part of the uplisting process, OTC Markets will handle Adia's Form 15c2-11, streamlining the broker-dealer quotation process and enhancing transparency. The company has also requested the Non-Objecting Beneficial Owners (NOBO) list to improve direct shareholder communication.
CEO Larry Powalisz emphasized that these strategic moves align with the company's commitment to transparency and growth. The uplisting is part of Adia's broader roadmap toward a potential Nasdaq Small Cap listing, aiming to enhance market credibility and expand its investor base while continuing to develop its clinic network and regenerative medicine solutions.
Positive
- Filing for OTCQB uplisting indicates market progression and enhanced visibility
- Successful completion of independent audit demonstrates financial compliance
- Streamlined 15c2-11 process through OTC Markets improves trading efficiency
- Strategic path toward potential Nasdaq Small Cap listing shows growth trajectory
Negative
- None.
News Market Reaction
On the day this news was published, ADIA declined 12.50%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Winter Park, Florida--(Newsfile Corp. - April 14, 2025) - Adia Nutrition Inc. (OTC Pink: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces that it has officially filed with OTC Markets Group for uplisting to the OTCQB Venture Market. This filing follows the successful completion of an independent audit with Astra Audit and Advisory LLC on April 1, 2025, marking a significant milestone in the company's commitment to enhancing visibility, liquidity, and shareholder value through its innovative stem cell therapies and premium nutritional products.
As part of this uplisting process, OTC Markets will handle Adia Nutrition's Form 15c2-11, a critical step under SEC regulations that enables broker-dealers to quote the company's securities. By having OTC Markets facilitate this streamlined review, Adia benefits from a more efficient path to public quotation compared to traditional FINRA filings. This process ensures current financial and operational information is publicly available, boosting transparency and investor confidence. The 15c2-11 completion will also enhance market maker participation, improving trading efficiency, liquidity, and price discovery-key advantages as Adia transitions to the OTCQB's higher reporting standards and broader investor reach.
Additionally, Adia Nutrition has requested the Non-Objecting Beneficial Owners (NOBO) list, a strategic move to strengthen shareholder engagement. Obtaining the NOBO list allows the company to directly communicate with street-name shareholders who do not object to sharing their contact details, bypassing intermediaries like brokers. This direct access enhances Adia's ability to share updates on its pioneering work-such as Umbilical Cord Stem Cell (UCB-SC) therapies and Autologous Hematopoietic Stem Cell Transplantation (aHSCT)-while building closer ties with investors and potentially increasing participation in corporate actions like voting or investment opportunities.
"We're thrilled to take this next step toward the OTCQB," said Larry Powalisz, CEO of Adia Nutrition Inc. "Filing for uplisting, leveraging OTC Markets for our 15c2-11, and requesting the NOBO list reflect our focus on transparency and growth. These moves not only elevate our market presence but also connect us more directly with the investors who believe in our mission to transform healthcare through stem cell innovation and nutritional excellence."
With this filing, Adia Nutrition is poised to capitalize on the OTCQB's benefits, including greater market credibility and access to a wider investor base, as it continues to expand its network of clinics and advance its science-backed solutions. The company remains on track with its broader roadmap toward a potential Nasdaq Small Cap listing, reinforcing its position as a pioneer in regenerative medicine.
For questions, inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247981
FAQ
What is the significance of Adia Nutrition's (ADIA) OTCQB uplisting filing in April 2025?
How will OTC Markets handling ADIA's Form 15c2-11 benefit the company?
What is the purpose of ADIA requesting the NOBO list in 2025?
What are ADIA's long-term market objectives beyond the OTCQB uplisting?
